(Total Views: 1058)
Posted On: 10/11/2020 1:34:26 PM
Post# of 151766
Re: ClosetInvestor #60716
60 minutes tonight will focus on Regeneron and Eli Lilly. I doubt Leronlimab or CYDY get mentioned. We should continue to press while therapies and monoclonal antibodies are hot news.
Perhaps another interview and learn from the mistakes on Fox. (yes there were mistakes)
Maybe some name recognition by saying Leronlimab as often as possible and maybe let listeners know they can get enrollment info at CytoDyn.com. (Of course put an obvious link to trial info on the front page.)
Remember 99% of listeners know almost nothing about monoclonal antibodies and have never heard of Leronlimab or CYDY. Stick to the basics. "Works by quieting the cytokine storm" is a great way to describe the MOA. Keep it simple remember the audience is not scientists.
Anyway I can dream. I have emailed Dr Kelly about Sara Eisen on CNBC. She has tweeted about Leronlimab and would be the perfect choice to interview with.
Perhaps another interview and learn from the mistakes on Fox. (yes there were mistakes)
Maybe some name recognition by saying Leronlimab as often as possible and maybe let listeners know they can get enrollment info at CytoDyn.com. (Of course put an obvious link to trial info on the front page.)
Remember 99% of listeners know almost nothing about monoclonal antibodies and have never heard of Leronlimab or CYDY. Stick to the basics. "Works by quieting the cytokine storm" is a great way to describe the MOA. Keep it simple remember the audience is not scientists.
Anyway I can dream. I have emailed Dr Kelly about Sara Eisen on CNBC. She has tweeted about Leronlimab and would be the perfect choice to interview with.
(2)
(0)Scroll down for more posts ▼
